Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g/m2) and granulocyte colony-stimulating factor in patients with multiple myeloma

Bone Marrow Transplantation

Volumn 17, Issue 5, 1996, Pages 691-697

  Goldschmidt, H ^a   Hegenbart, U ^a   Haas, R ^a   Hunstein, W ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

High dose cyclophosphamide; Multiple myeloma; Peripheral blood progenitor cell mobilization

Indexed keywords

ALKYLATING AGENT; AMPHOTERICIN B; CD19 ANTIGEN; CD34 ANTIGEN; COLISTIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; MESNA; ONDANSETRON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ALOPECIA; ARTICLE; AUTOTRANSPLANTATION; B LYMPHOCYTE; CELL MOTILITY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HEADACHE; HEMORRHAGIC CYSTITIS; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LEUKAPHERESIS; MALE; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BLOOD COMPONENT REMOVAL; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; FILGRASTIM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; TRANSPLANTATION, AUTOLOGOUS;

EID: 0029973425     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Billadeau D, Ahmann G, Greipp P, Van Ness B. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J Exp Med 1993; 178: 1023-1031.
2. Alexanian R. Dimopoulos M. The treatment of multiple myeloma. New Engl J Med 1994; 330: 484-489.
3. Jagannath S, Vesole DH, Glen L et al. Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood 1992; 80: 1666-1672.
4. Fermand J-P, Chevret S. Ravaud P et al. High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients. Blood 1993; 82: 2005-2009.
5. Lenhard RE, Oken MM, Barnes JM et al. High-dose cyclophosphamide. An effective treatment for advanced refractory multiple myeloma. Cancer 1984; 53: 1456-1460.
6. To LB, Shepherd KM, Haylock DN et al. Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood. Exp Hematol 1990; 18: 442-447.
7. Rosenfeld CS, Shadduck RK, Zeigler ZR et al. Cyclophosphamide-mobilized peripheral blood stem cells in patients with lymphoid malignancies. Bone Marrow Transplant 1995; 15: 433-438.
8. Boiron J-M, Marit G, Fabères C et al. Collection of peripheral blood stem cells in multiple myeloma following single high-dose cyclophosphamide with and without recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF). Bone Marrow Transplant 1993; 12: 49-55.
9. Siena S, Bregni M, Brando B et al. Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1989; 74: 1905-1914.
10. Hohaus S. Goldschmidt H, Ehrhardt R. Haas R. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF. Exp Hematol 1993; 21: 508-514.
11. Haas R, Möhle R, Frühauf S et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787-3794.
12. Tricot G, Jagannath S, Vesole D et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favourable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588-596.
13. Bergsagel PL, Smith AM, Szczepek A et al. In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56. and monotypic Ig light chain. Blood 1995; 85: 436-447.
14. Goldschmidt H. Moos M, Cremer F et al. Antigenic profile and PCR-analysis of peripheral blood progenitor cell autografts in multiple myeloma. Blood 1994; 84: 385a (abstr.).
15. Dune B, Salmon S. A clinical staging system for multiple myeloma. Cancer 1975; 36: 842-852.
16. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publications, Geneva, 1979.
17. Kotasek D, Shepherd KM, Sage RE et al. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant 1992: 9: 11-17.
18. 2 in patients with advanced cancer. Aust NZ J Med 1992; 22: 660-664.
19. Appelbaum FR, Strauchen JA, Graw RG et al. Acute lethal carditis caused by high-dose combination chemotherapy. A unique clinical and pathological entity. Lancet 1976; 1: 58-62.
20. Demuynck H, Delforge M, Verhoef G et al. Comparative study of peripheral blood progenitor cell collection in patients with multiple myeloma after single-dose cyclophosphamide combined with rhGM-CSF or rhG-CSF. Br J Haematol 1995; 90: 384-392.
21. To LB, DN Haylock, T Dowse et al. A comparative study of the phenotype and proliferative capacity of peripheral blood (PB) CD34+ cells mobilized by four different protocols and those of steady-phase PB and bone marrow CD34+ cells. Blood 1994; 84: 2930-2939.
22. + hematopoietic progenitor cells. Blood 1995; 85: 1936-1943.
23. Pilarski LM, Smith AM, Mant MJ et al. The malignant lineage in myeloma: dissemination of disease. Vth International Workshop on Multiple Myeloma, 1995, La Baule, (abstr. 3.27).
24. Pilarski LM, Belch AJ. Circulating monoclonal B cells expressing p-glycoprotein may be a reservoir of multidrug resistant disease in multiple myeloma. Blood 1994; 85: 436-447.
25. Laufman LR, Jones JJ, Momce B, Hee Han C. Case report of a lethal cardiac toxic effect following high-dose cyclophos-phamide. J Nat Cancer Inst 1995: 87: 539-540.
26. Evans BD, Smith IE, Clutterbuck RD. Millar JL. Prevention of acute deaths in mice after very high dose cyclophosphamide by divided dose schedule. Br J Cancer 1984; 49: 43-47.